Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese - PubMed (original) (raw)

. 2020 Feb;27(2):127-134.

doi: 10.1111/jvh.13212. Epub 2019 Oct 28.

Affiliations

Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese

Rongrong Yang et al. J Viral Hepat. 2020 Feb.

Abstract

The aim of this retrospective study was to observe hepatitis B surface antigen (HBsAg) seroclearance and explore predictors of HBsAg loss in HIV/HBV-co-infected patients receiving long-term lamivudine or both tenofovir and lamivudine containing therapies. Quantification of HBsAg, hepatitis B e antigen and HBV DNA before and after initiation of HBV-active antiretroviral therapy in a total of 268 HIV/HBV-co-infected patients started treatment between 2005 and 2017 were performed. Over a median of 65.63 months of follow-up, 10 (3.7%) were observed HBsAg loss and the quantification of HBsAg in 7 (2.6%) patients were less than 50 IU/mL. With the prolongation of antiretroviral therapy duration time, the rates of HBsAg seroclearance tended to increase gradually, rising from 1.8% (3/163) during 2-4 years treatment to 29.4% (10/34) after antiretroviral therapy for up to 10 years. Lower baseline qHBsAg and HBV DNA levels and strong 12-month declines in qHBsAg were significantly associated with HBsAg seroclearance. The event of HBsAg seroclearance is uncommon among Chinese individuals with HIV/HBV co-infection who have been treated with anti-HBV containing antiretroviral therapy, and lifelong therapy for HBV is needed for HIV/HBV co-infected patients. Baseline qHBsAg and HBV DNA levels and qHBsAg decline rate were predictors for HBsAg seroclearance.

Keywords: HBsAg seroclearance; antiretroviral therapy; hepatitis B virus; human immunodeficiency virus.

© 2019 John Wiley & Sons Ltd.

PubMed Disclaimer

References

REFERENCES

    1. WHO. Progress report 2011: global HIV/AIDS response. http://www.who.int/hiv/pub/progress_report2011/en/index.html. Accessed November 30, 2011.
    1. Rong-Rong Y, Xi-en G, Shi-cheng G, et al. Interaction of hepatitis B and C viruses in patients infected with HIV. J Acquir Immune Defic Syndr. 2008;48(4):491-492.
    1. Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57(1):249-257.
    1. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271-278.
    1. Chen C-J, Yang H-I, Iloeje UH, et al. Hepatitis B virus NA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):s72-s84.

MeSH terms

Substances

LinkOut - more resources